How to Use AI for an Allergy & Immunology Practice in 2026: A Pragmatic Owner's Playbook

June 5, 2026 · 14 min read · How-To Guide

TL;DR

For a 1-5 MD allergy + immunology practice in 2026, AI is a SOAP + prior-auth + immunotherapy QC + patient-education accelerator, not the allergist. Run AI inside HIPAA-compliant tooling with BAAs, anchor every clinical workflow to AAAAI/ACAAI/JCAAI Practice Parameters, keep USP 797 audit-ready binders current after the Nov 1 2023 revision, layer state AI-scribe consent (CA AB 3030, TX SB 815, UT HB 452, IL HB 1806), and let the allergist sign every output. Owners typically see 25-45 percent note-time reduction with zero parameter breaches.

Why this matters now

The 2024-2026 wave of biologic launches (Tezspire, Adbry, Rinvoq, Cibinqo, Eohilia, Takhzyro, Orladeyo, Garadacimab) has multiplied prior-auth complexity. USP 797 revised Nov 1 2023 raised the SCIT mixing audit floor. State AI-scribe consent rules took effect across CA, TX, UT, IL between 2025 and 2026. The single-shingle allergist who pairs ambient AI with disciplined practice-parameter alignment wins on note time, prior-auth turnaround, and biologic adherence; the practice that bolts AI on without a parameter map and a 797 binder gets a state-board complaint or a denied biologic.

The 7-layer AI stack for an allergy & immunology practice

Layer	Job	Tools
1. Front-desk + intake	Scheduling, eligibility, AI-scribe consent banner	Phreesia, NexHealth, Klara, Doctible, Solutionreach, Weave, Luma Health, Relatient, OhMD
2. Ambient SOAP + EHR	Visit note, problem-list, orders	DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai, Augmedix, Nabla; EHRs Epic + Cerner + athenaOne + eClinicalWorks + NextGen + AdvancedMD + Modernizing Medicine EMA Allergy + AllergyEHR
3. Skin-testing + extract mixing + USP 797	Build sheets, BUD tracking, audit binder	AllergyEHR, AllerView Pro, MyImmunoTrek, ImmunoTek, AllergyMD, Greer Mixing Module, ALK Mixing Module, JubilantHollisterStier Software, USP 797 audit tools (CompounDoc, Pharmacy Compliance Tracker)
4. Prior-auth + biologic + step-therapy	Tezspire, Dupixent, Xolair, Nucala, Fasenra, Adbry, Rinvoq, Cibinqo, Eohilia, Takhzyro, Orladeyo	CoverMyMeds, Glidian, Surescripts Prior Auth, Office Ally, Availity, Waystar, Myndshft, Banjo Health, Cohere Health, Real Time Medical Systems
5. Patient-education + adherence	Asthma + AD + CSU + EoE + HAE handouts, recall	Klara, Weave AI, NexHealth, Phreesia, Healthwise, Wolters Kluwer UpToDate Patient, Mytonomy, Twistle, Welkin, Memora Health
6. MIPS + quality + RCM	Quality measures, denials, payer mix	MDinteractive, MIPSpro, Healthmonix, Mingle Health, Office Ally, Availity, Waystar, Athenahealth Collector, AdvancedMD RCM
7. Reviews + recruiting + scorecard	FTC-safe reviews, recruiting, owner KPI	BirdEye, Podium, NiceJob, Swell, Doximity, PracticeMatch, Indeed, Glassdoor, Tableau Pulse, Power BI Copilot

10 copy-paste prompts for an allergy & immunology practice

1. New-patient allergy + immunology intake synthesis

From the new-patient questionnaire + portal symptom diary + uploaded outside records, draft: chief complaint, HPI, ROS, PMH, allergy history (drug, food, environmental, venom, latex), immunization, family history, social, ACT/ACQ-7, SNOT-22, UAS7, EASI/POEM, EoE Symptom Score, HAE attack log if applicable. Flag red-flags: anaphylaxis history, asthma not-well-controlled, eosinophilia, recurrent infections, angioedema without urticaria. Output is a draft SOAP shell; the allergist owns history and physical, signs.

2. Ambient allergy + immunology SOAP with CPT + ICD-10

Given the ambient transcript of the visit + the patient chart, draft a SOAP note with: S (interval history, symptom scores), O (vitals, focused exam, in-office tests, FeNO, spirometry, peak flow, in-office skin test if performed), A (problem list with ICD-10 J45 asthma, J30 allergic rhinitis, L20 atopic dermatitis, L50 urticaria, K20.0 EoE, T78.40XA other allergy, D84 immunodeficiency, D84.1 HAE), P (medications, immunotherapy plan, biologic, follow-up, patient education, anaphylaxis action plan). Include CPT 99202-99215 E/M, 95004-95071 testing, 95115-95117 SCIT injection, 95144-95170 mixing, 86003 IgE, 95180 desensitization where applicable. Allergist reviews + signs.

3. Tezspire / Dupixent / Xolair / Nucala / Fasenra prior-auth letter for severe asthma

Given the chart for [patient] with severe asthma and ACT under 20 / ACQ-7 over 1.5 / 2-or-more steroid bursts in the last 12 months, draft a payer prior-auth letter mapping to GINA 2024 Step 5 + AAAAI/ACAAI Severe Asthma Algorithm + the payer's medical-policy criteria. Include phenotype data (blood eos, total IgE, FeNO, exhaled FeNO, sputum eos), step-therapy completion (ICS-LABA at high dose, LAMA, OCS bursts, prior biologic if any), exacerbation history, comorbidities. Cite the FDA label, NCCN/AAAAI algorithm, and payer policy by name. Allergist signs.

4. Dupixent / Adbry / Rinvoq / Cibinqo prior-auth for atopic dermatitis

For [patient] with moderate-to-severe AD and EASI over 16 / IGA 3-or-4 / BSA over 10 percent / DLQI over 10 / failure of medium-to-high potency topical corticosteroid + topical calcineurin inhibitor over 12 weeks, draft a prior-auth letter mapping to the JTF AD 2023 + AAD 2024 + payer policy. Include FDA Boxed Warning JAK 2021 ORAL Surveillance counseling for Rinvoq + Cibinqo, screening labs (TB, hep B/C, lipids, CBC), and step-therapy compliance. Allergist signs.

5. Takhzyro / Orladeyo / Garadacimab / Berinert / Firazyr prior-auth for HAE

For [patient] with confirmed HAE Type I / II (low C4, low C1-INH function, family history) or HAE-nC1-INH, draft a prior-auth letter for prophylaxis (Takhzyro, Orladeyo, Garadacimab, Haegarda, Cinryze) or on-demand (Berinert, Firazyr, Ruconest, Kalbitor) per WAO/EAACI 2021 + US HAEA Medical Advisory Board 2023 + payer medical policy. Include attack frequency, location, severity, prior treatment failures, ER/admission history, and quality-of-life impact. Allergist signs.

6. Subcutaneous immunotherapy build sheet QC + USP 797 BUD tracker

Given the patient's positive aeroallergen panel + clinical correlation, draft an SCIT build sheet with: vial concentration (1:1, 1:10, 1:100, 1:1000), allergen dose per vial (BAU, AU/mL, PNU, w/v), maintenance dose target per AAAAI Practice Parameter for Allergen Immunotherapy 2011 + 2024 ICAR-IT, vial expiration with USP 797 Beyond-Use-Date logic, label content (patient + DOB + concentration + BUD + lot), ISO classification of mixing area, garbing + cleaning log entries. Compounding pharmacist or supervising allergist signs.

7. Anaphylaxis action plan + epinephrine auto-injector education

Draft a personalized anaphylaxis action plan per AAAAI/ACAAI 2020 + 2023 update + AAP 2017 with: trigger (peanut, tree-nut, sesame, fish, shellfish, milk, egg, wheat, soy, drug, venom, latex, exercise-induced, idiopathic), warning signs by system, epinephrine dose by weight (EpiPen, Auvi-Q, neffy nasal-spray, generic auto-injector), call-911 instruction, second-dose timing, antihistamine adjunct, school 504 plan section, and a refill calendar. Allergist signs.

8. Drug + food + venom oral challenge + desensitization protocol drafter

For [patient] with reported allergy to [drug or food], draft a graded oral challenge or desensitization protocol per JTF Drug Allergy 2010 + 2022 + ACAAI Food Allergy 2014 + LEAP/EAT 2015. Include risk stratification (low/moderate/high), pre-medication, step doses, observation interval, vital monitoring, rescue meds, stop criteria, and post-procedure observation per CPT 95076-95079. Confirm staffing for ACLS + epinephrine + IV access. Allergist signs + supervises.

9. MIPS MVP quality + improvement-activity dashboard

Pull the practice MIPS dashboard for the current performance period and map to MVP Promoting Wellness + Optimizing Chronic Disease Management. Show: quality measures (Asthma Assessment, Tobacco Use, BMI Screening, Influenza, Pneumococcal, Medication Reconciliation), improvement activities, promoting interoperability, cost. Highlight gaps and rank patients-to-recall to improve quality scoring. Practice administrator + allergist review.

10. Owner monthly scorecard

Build a 1-page monthly scorecard for the allergist-owner with: new-patient slots filled, no-show rate, SCIT adherence (percent of patients on schedule), biologic prior-auth approval rate + average turnaround, drug-challenge volume + complication rate, in-office testing volume, top-5 denied-claim reasons, AR aging, payer mix, MIPS gap list, USP 797 audit-binder status, and state AI-scribe consent compliance. Two recommended actions for next month.

The 12-item compliance floor

HIPAA 45 CFR 160 + 164 with BAA on every AI vendor + minimum-necessary access.
AAAAI/ACAAI/JCAAI Practice Parameters for asthma, AR, AD, urticaria, anaphylaxis, food allergy, drug allergy, EoE, PI, HAE, SCIT/SLIT.
USP 797 (revised Nov 1 2023) compounding standards for SCIT extract mixing + audit binder + competency.
FDA-cleared AI-SaMD only for ancillary clinical decision-support; allergist makes final clinical decision.
State AI-scribe consent (CA AB 3030, TX SB 815, UT HB 452, IL HB 1806, NY S1331A pending) + FSMB Model Policy on AI 2024.
State medical-board licensure + DEA registration + state board-of-pharmacy interpretation of 797 for in-office mixing.
CMS MIPS MVP Promoting Wellness + Optimizing Chronic Disease + applicable quality measures.
AKS / Stark / Sunshine ($13.46 / $134.49 FY 2026) on biologic + skin-test reagent + device rep relationships.
Sunshine Act + state-specific reporting for biologic samples + speaker programs.
FDA Boxed Warning compliance for JAK inhibitors (Rinvoq, Cibinqo) per ORAL Surveillance 2021 + label.
FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 ($51,744-per-violation FY 2026) + state medical-board advertising rules.
State PDMP + controlled-substance rules where applicable (oral steroid + epinephrine refill not PDMP-tracked, but immunomodulators may trigger state-specific rules).

60-day rollout plan

Week 1-2: HIPAA BAA refresh on every AI vendor. Add state AI-scribe consent banner to new-patient packet. Digitize USP 797 audit binder. Pilot one ambient AI tool on 2 friendly visits.
Week 3-4: Expand ambient AI to all E/M with allergist sign-off. Stand up CoverMyMeds / Glidian / Surescripts PA workflow for biologic prior-auth.
Week 5-6: AI-drafted asthma + AD + CSU + EoE + HAE handouts. AI-drafted anaphylaxis action plan template. SCIT build-sheet QC + BUD-alarm dashboard.
Week 7-8: AI-drafted MIPS gap list + recall calendar. Owner scorecard live. Quarterly state AI-consent + USP 797 + HIPAA self-audit.

8 mistakes that sink allergy practice AI rollouts

Letting AI auto-finalize SOAP notes without allergist sign-off. Practice-parameter and state-board exposure.
Ingesting PHI into a vendor AI without a signed BAA. HIPAA penalties up to $2,134,831 per category per year (FY 2025).
Skipping USP 797 audit-binder digitization. State board-of-pharmacy inspections increasingly target SCIT mixing.
Submitting biologic prior-auth without phenotype + biomarker + step-therapy data — instant denial.
Ignoring state AI-scribe consent in CA / TX / UT / IL. Consumer complaints stack.
Skipping FDA Boxed Warning counseling on JAK inhibitors. Med-mal exposure.
Auto-replying to Google reviews with cookie-cutter language that violates FTC Endorsement Guides or Fake Reviews Rule.
Treating AI immunotherapy build-sheet output as final without compounding-pharmacist or allergist verification. Patient-safety event.

FAQs

Where does AI safely sit inside an allergy & immunology practice under HIPAA, the AAAAI/ACAAI/JCAAI Practice Parameters, and FDA AI-SaMD rules?

AI is a documentation, prior-auth, and triage accelerator — not the prescriber. The board-certified allergist still owns history-taking, skin-testing interpretation, biologic selection, anaphylaxis management, and final orders. AAAAI/ACAAI/JCAAI Practice Parameters (Asthma 2020 + GINA 2024 + 2025 update, Allergic Rhinitis 2017 ICAR 2023, Atopic Dermatitis JTF 2023, Chronic Urticaria 2014 + EAACI 2022, Anaphylaxis 2020 + 2023 update, Food Allergy 2014 + NIAID 2017 + LEAP 2015, Drug Allergy 2010 + 2022, Eosinophilic Esophagitis 2020, Primary Immunodeficiency JCAAI 2015 + IDF 2024, Hereditary Angioedema 2020 + 2023, Sublingual + Subcutaneous Immunotherapy 2011 + 2024 ICAR-IT). FDA-cleared AI-SaMD (Aidoc / Rad AI / Gleamer / Smarter-Dx) for ancillary imaging is read-as-second-opinion. AI runs inside HIPAA-compliant tooling with BAAs and never makes a final clinical decision.

How do biologic prior-auth and step-therapy rules shape an AI workflow for asthma + chronic spontaneous urticaria + EoE + atopic dermatitis + nasal polyposis + HAE biologics?

Most payers gate Tezspire, Dupixent, Xolair, Nucala, Fasenra, Cinqair, Adbry, Rinvoq, Cibinqo, Eohilia, Dupixent EoE, Takhzyro, Orladeyo, Berinert, Firazyr, Ruconest, Haegarda, Cinryze, and Garadacimab through phenotype + biomarker + step-therapy pathways: blood eos, total IgE, FeNO, ACQ-7 / ACT, UAS7, EoE Symptom Score, EASI, AD Severity, SNOT-22, HAE attack frequency. State step-therapy reform laws (CA SB 313, NY S2849A, TX SB 875, FL HB 1003, IL SB 2541, plus 30+ other states) require timely override processes when the documented exception criteria are met. AI drafts the prior-auth letter mapping the chart to the NCCN/AAAAI/JTF biologic algorithm + payer policy + Milliman MCG / InterQual criteria; the allergist signs.

What does USP 797 (revised effective Nov 1 2023) require for in-office subcutaneous immunotherapy mixing, and how does AI help us stay audit-ready?

USP <797> revised Nov 1 2023 governs Compounded Sterile Preparations including allergen extracts. SCIT mixing is treated as Category 1 (12-hour Beyond-Use Date at controlled room temp, 24 hours refrigerated) when not prepared in an ISO Class 5 area but in a SCA — though most practices store at refrigerator temp and follow vendor-specific stability data. Practice must document: hand-hygiene + garbing, cleaning + disinfection logs, vial labeling with patient + concentration + Beyond-Use Date, environmental monitoring per state board-of-pharmacy interpretation, and competency assessment of compounding personnel. State boards of pharmacy interpret 797 differently; CA requires extract-mixing-specific exemption letters, NY requires Article 137 NPS pharmacy registration analysis. AI builds the audit-ready binder + competency log + BUD-alarm dashboard but the supervising physician + state-board contact remain human.

How do state AI-scribe consent laws and CMS MIPS MVP for allergy & immunology shape what we can document and bill?

CA AB 3030 (effective Jan 1 2025), TX SB 815 (effective Sep 1 2025), UT HB 452 AI Mental Health Policy Act, IL HB 1806 (effective Jan 1 2026), NY S1331A (pending), and FSMB Model Policy on AI 2024 require generative-AI clinical-content disclosure when AI generates patient-facing communications. Practical: add a notice-of-AI-use to the new-patient packet and the visit summary. CMS MIPS MVP Advancing Care for Allergy is folded under broader MVPs (Promoting Wellness, Optimizing Chronic Disease, Improving Care for Lower Extremity Joint Repair) but the allergy practice typically maps to MVP Promoting Wellness + quality measures Asthma Assessment / Tobacco Use / BMI Screening / Influenza / Pneumococcal / Medication Reconciliation. CPT codes that AI accelerates: 99202-99215 E/M, 95004-95071 percutaneous + intradermal + patch + challenge, 95115-95117 SCIT injection, 95144-95170 SCIT extract preparation, 95165 multi-dose vial, 95180 desensitization, 86003 specific IgE, 86353 LTT, 86343 leukocyte histamine, 86001 IgG to allergens (limited reimbursement).

What is a realistic 90-day ROI for a 1-5 MD allergy & immunology practice rolling out AI without breaking HIPAA, AAAAI/ACAAI Practice Parameters, USP 797, or state AI-scribe consent rules?

Days 1-30: HIPAA BAA refresh, USP 797 audit-binder digitization, ambient AI tool selection (DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai), state AI-scribe consent banner added to the new-patient portal. Days 31-60: AI-drafted SOAP for every E/M with allergist sign-off, AI prior-auth packet generator for Tezspire/Dupixent/Xolair/Nucala/Fasenra/Adbry/Rinvoq/Eohilia/Takhzyro/Orladeyo, AI immunotherapy build sheet QC. Days 61-90: AI-drafted asthma + AD + CSU + EoE + HAE patient-education handouts, AI MIPS dashboard refresh, AI biologic adherence recall. Realistic outcome: 25-45 percent reduction in note-charting time, 30-50 percent reduction in prior-auth turnaround, zero practice-parameter or state-board breaches when the allergist signs every output.

Sources + further reading

AAAAI / ACAAI / JCAAI Practice Parameters (asthma, AR, AD, urticaria, anaphylaxis, food, drug, EoE, PI, HAE, SCIT/SLIT)
GINA 2024 + 2025 update Global Initiative for Asthma
USP General Chapter <797> revised November 1 2023
FDA Boxed Warning JAK inhibitors per ORAL Surveillance 2021
FSMB Model Policy on Artificial Intelligence in Medical Practice 2024
State AI-scribe consent: CA AB 3030, TX SB 815, UT HB 452, IL HB 1806, NY S1331A
CMS MIPS MVP Promoting Wellness + Optimizing Chronic Disease Management
State step-therapy reform: CA SB 313, NY S2849A, TX SB 875, FL HB 1003, IL SB 2541
FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465
HIPAA 45 CFR 160 + 164 + HITECH

Related guides

← Back to all guides